Organization
Abbisko Therapeutics Co., Ltd., Shanghai, China
2 abstracts
Abstract
First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, Jiangsu Province Hospital, Nanjing, China, Winship Cancer Institute, Atlanta, GA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Henan Cancer Hospital, Zhengzhou, China,
Abstract
Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update.Org: Abbisko Therapeutics Co., Ltd., Shanghai, China,